glp 1 gip dual agonist weight loss GIPR/GLP-1R therapies for diabetes and loss—chemistry, physiology, and clinical applications GIPR/GLP-1R dual agonist therapies for
Description
10.1517/17425255.2012.686603 166 ScheenA
It is most suitable for people who have not been able to achieve significant weight loss through diet and exercise alone
Retatrutide also remains investigational, with ClinicalTrials.gov listing active or recently updated Phase 3 research records as of May 2026
Rapid weight loss, however, can also cause bone density loss
